; and (4) Federal funding necessary to achieve substantial reductions in sleep and circadian health disorders in racial and ethnic minority communities. K Kidney Disease Research, Surveillance, Prevention, and Treatment 797. Kidney disease, research, surveillance, prevention, and treatment (a) Short title This section may be cited as the Kidney Disease Research, Surveillance, Prevention and Treatment Improvement Act of 2020 . (b) Findings Congress makes the following findings: (1) Kidney diseases impact 37 million Americans. (2) African Americans comprise just 13 percent of the United States population, but 33 percent of the United States dialysis patient population. Compared to Caucasians, kidney failure prevalence is about 3.7 times greater in African Americans, 1.4 times greater in Native Americans, and 1.5 times greater in Asian Americans. (3) Peritoneal dialysis and home hemodialysis use is 40–50 percent lower among African Americans and Hispanics. (4) Every racial/ethnic minority group in the United States is significantly less likely to be treated with home dialysis than Whites, and demographic and clinical characteristics are insufficient to explain this differential use. (5) African Americans on dialysis, irrespective of dialysis modality, and Hispanics undergoing PD or in-center HD, are significantly less likely than their White counterparts to receive a kidney transplant. (6) African Americans, Hispanics, and Asian Americans are less likely to receive living donor kidney transplants than Whites. Efforts to reduce disparities in live donor kidney transplantation for African-American, Hispanic, and Asian patients with kidney failure have been unsuccessful. (7) Medicare and Medicaid patients are less likely to receive a preemptive transplant from a deceased donor compared to private insurance patients (5 percent and 11 percent versus 24 percent), and Black and Hispanic patients are less likely to receive a preemptive transplant from a deceased donor compared with White patients even after changes to the